Skip to main content

Advertisement

Log in

Molecular diagnosis of the Portuguese founder mutation BRCA2 c.156_157insAlu

  • Letter to the editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

References

  1. Machado P, Vaz F (2008) Caution should be taken in the methodology used to confirm c.156_157insAlu BRCA2 mutation. Breast Cancer Res Treat (Epub ahead of print Jul 17, 2008). doi:10.1007/s10549-008-0124-0

  2. Peixoto A, Santos C, Rocha P et al (2008) The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. Breast Cancer Res Treat (Epub ahead of print Mar 25, 2008). doi:10.1007/s10549-008-9978-4

  3. Teugels E, De Brakeleer S, Goelen G (2005) De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes. Hum Mutat 26:284. doi:10.1002/humu.9366

    Article  PubMed  Google Scholar 

  4. Machado PM, Brandao RD, Cavaco BM et al (2007) Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 25:2027–2034. doi:10.1200/JCO.2006.06.9443

    Article  PubMed  CAS  Google Scholar 

  5. Díez O, Osorio A, Durán M et al (2003) Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 22:301–312. doi:10.1002/humu.10260

    Article  PubMed  Google Scholar 

  6. van der Hout AH, van den Ouweland AM, van der Luijt RB et al (2006) A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat 27:654–666. doi:10.1002/humu.20340

    Article  PubMed  Google Scholar 

  7. Human Genome Variation Society (HGVS). http://www.hgvs.org/

  8. Nordling M, Karlsson P, Wahlstrom J et al (1998) A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family. Cancer Res 58:1372–1375

    PubMed  CAS  Google Scholar 

  9. Zou J, Hirose Y, Siddique H et al (1999) Structure and expression of variant BRCA2a lacking the transactivation domain. Oncol Rep 6:437–440

    PubMed  CAS  Google Scholar 

  10. Bonnet C, Krieger S, Vezain M et al (2008) Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet 45:438–446. doi:10.1136/jmg.2007.056895

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Manuel R. Teixeira.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peixoto, A., Santos, C., Rocha, P. et al. Molecular diagnosis of the Portuguese founder mutation BRCA2 c.156_157insAlu. Breast Cancer Res Treat 117, 215–217 (2009). https://doi.org/10.1007/s10549-008-0214-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-008-0214-z

Keywords

Navigation